| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology, Pathobiology, and Genetics |
Departments of 1 Medical Genetics and 2 Health Sciences Laboratory Animal Services, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
Requests for reprints: Susan E. Andrew, Department of Medical Genetics, University of Alberta, Room 8-33, Medical Sciences Building, Edmonton, Alberta, Canada T6G 2H7. Phone: 780-492-1128; Fax: 780-492-1998; E-mail: susan.andrew{at}ualberta.ca.
Inheritance of a germline mutation in one of the DNA mismatch repair genes predisposes human individuals to hereditary nonpolyposis colorectal cancer, characterized by development of tumors predominantly in the colon, endometrium, and gastrointestinal tract. Mice heterozygous for a mismatch repairnull mutation generally do not have an increased risk of neoplasia. However, mice constitutively lacking mismatch repair are prone to tumor development from an early age, particularly thymic lymphomas. Mismatch repairdeficient mice crossed to Apc+/ mice develop an increased spontaneous intestinal tumor incidence, demonstrating that the tumor spectrum can be genetically influenced. Here, we bred Msh2- and Msh6-deficient mice to athymic nude mice, hypothesizing that a broader tumor spectrum may be observed if mice are able to survive longer without succumbing to thymic lymphomas. However, Msh2/;Foxn1nu/nu and Msh6/;Foxn1nu/nu mice developed primarily early-onset lymphoblastic lymphomas. Using B-cellspecific markers, we found these tumors to be predominately B-cell in origin. The development of hematologic malignancy in the mouse, even in the absence of a thymus, parallels the development of B- and T-cell lymphoma and leukemia in the few rare mismatch repairnull human patients that have been identified. The persistent development of hematologic malignancy both in the mouse and in human patients deficient in mismatch repair leads us to implicate mismatch repair as an important repair mechanism in normal B- and T-cell development. Thus, mismatch repairdeficient mice may prove to be a good model to study human hematologic malignancy.
Key Words: hematologic malignancy mismatch repair mouse modeling microsatellite instability DHJH gene rearrangement B-cells DNA Damage and repair mechanism Leukemias and lymphomas Animal models of cancer Familial and hereditary cancers Biomarkers of DNA Damage/Repair, Exposure and Phenotype
This article has been cited by other articles:
![]() |
M. T. Russo, G. De Luca, I. Casorelli, P. Degan, S. Molatore, F. Barone, F. Mazzei, T. Pannellini, P. Musiani, and M. Bignami Role of MUTYH and MSH2 in the Control of Oxidative DNA Damage, Genetic Instability, and Tumorigenesis Cancer Res., May 15, 2009; 69(10): 4372 - 4379. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wu, J. R. Darce, S. K. Chang, G. S. Nowakowski, and D. F. Jelinek Alternative splicing regulates activation-induced cytidine deaminase (AID): implications for suppression of AID mutagenic activity in normal and malignant B cells Blood, December 1, 2008; 112(12): 4675 - 4682. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. C. Young, A. M. Keuling, R. Lai, P. N. Nation, V. A. Tron, and S. E. Andrew The associated contributions of p53 and the DNA mismatch repair protein Msh6 to spontaneous tumorigenesis Carcinogenesis, October 1, 2007; 28(10): 2131 - 2138. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. C. Chao and S. M. Lipkin Molecular models for the tissue specificity of DNA mismatch repair-deficient carcinogenesis Nucleic Acids Res., February 6, 2006; 34(3): 840 - 852. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |